Prioritising access to cancer drugs

Affiliations

¹ Division of Medical Oncology and Hematology, Department of Medicine, The Princess Margaret Cancer Centre, Toronto ON, M5G 2M9, Canada.
² Centre for Big Data Research in Health, UNSW, Sydney, Australia; Menzies Centre for Health Policy, University of Sydney, Australia.
³ Collaboration for Cancer Outcomes, Research and Evaluation, South West Clinical School, University of New South Wales, Sydney, Australia.
⁴ Division of Medical Oncology and Hematology, Department of Medicine, The Princess Margaret Cancer Centre, Toronto ON, M5G 2M9, Canada; Collaboration for Cancer Outcomes, Research and Evaluation, South West Clinical School, University of New South Wales, Sydney, Australia. Electronic address: brooke.wilson@uhn.ca.

Comment

Mitchell J Elliott et al. Lancet Oncol. 2022 Jan.

. 2022 Jan;23(1):e1.

doi: 10.1016/S1470-2045(21)00641-0.

¹ Division of Medical Oncology and Hematology, Department of Medicine, The Princess Margaret Cancer Centre, Toronto ON, M5G 2M9, Canada.
² Centre for Big Data Research in Health, UNSW, Sydney, Australia; Menzies Centre for Health Policy, University of Sydney, Australia.
³ Collaboration for Cancer Outcomes, Research and Evaluation, South West Clinical School, University of New South Wales, Sydney, Australia.
⁴ Division of Medical Oncology and Hematology, Department of Medicine, The Princess Margaret Cancer Centre, Toronto ON, M5G 2M9, Canada; Collaboration for Cancer Outcomes, Research and Evaluation, South West Clinical School, University of New South Wales, Sydney, Australia. Electronic address: brooke.wilson@uhn.ca.

No abstract available

Conflict of interest statement

We declare no competing interests. BEW is supported as a National Breast Cancer Foundation of Australia International Fellow.

Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey.
Fundytus A, Sengar M, Lombe D, Hopman W, Jalink M, Gyawali B, Trapani D, Roitberg F, De Vries EGE, Moja L, Ilbawi A, Sullivan R, Booth CM. Fundytus A, et al. Lancet Oncol. 2021 Oct;22(10):1367-1377. doi: 10.1016/S1470-2045(21)00463-0. Epub 2021 Sep 21. Lancet Oncol. 2021. PMID: 34560006 Free PMC article.
Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study.
Basu P, Malvi SG, Joshi S, Bhatla N, Muwonge R, Lucas E, Verma Y, Esmy PO, Poli URR, Shah A, Zomawia E, Pimple S, Jayant K, Hingmire S, Chiwate A, Divate U, Vashist S, Mishra G, Jadhav R, Siddiqi M, Sankaran S, Prabhu PR, Kannan TPRA, Varghese R, Shastri SS, Anantharaman D, Gheit T, Tommasino M, Sauvaget C, Pillai MR, Sankaranarayanan R. Basu P, et al. Lancet Oncol. 2021 Nov;22(11):1518-1529. doi: 10.1016/S1470-2045(21)00453-8. Epub 2021 Oct 8. Lancet Oncol. 2021. PMID: 34634254 Free PMC article.
Prioritising access to cancer drugs.
Puyat CVM, Eala MAB, Dee EC, Tantengco OAG, Cruz ARDP, Faylona EA, Germar MJV, Sacdalan DL. Puyat CVM, et al. Lancet Oncol. 2022 Jan;23(1):e2. doi: 10.1016/S1470-2045(21)00637-9. Lancet Oncol. 2022. PMID: 34973227 No abstract available.